Your browser doesn't support javascript.
loading
Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis.
Soria, Francesco; Black, Peter C; Fairey, Adrian S; Cookson, Michael S; Yu, Evan Y; Kassouf, Wassim; Dall'Era, Marc A; Sridhar, Srikala S; McGrath, John S; Wright, Jonathan L; Thorpe, Andrew C; Morgan, Todd M; Daneshmand, Siamak; Holzbeierlein, Jeff M; Bivalacqua, Trinity J; North, Scott; Barocas, Daniel A; Lotan, Yair; Grivas, Petros; Stephenson, Andrew J; Shah, Jay B; van Rhijn, Bas W; Spiess, Philippe E; Shariat, Shahrokh F; Gontero, Paolo.
Afiliación
  • Soria F; Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy.
  • Black PC; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
  • Fairey AS; University of Alberta, Edmonton, AB, Canada.
  • Cookson MS; Department of Urology, University of Oklahoma College of Medicine, Oklahoma City, OK, USA.
  • Yu EY; Department of Medicine, Division of Oncology, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Kassouf W; Department of Surgery (Division of Urology), McGill University Health Center, Montreal, Canada.
  • Dall'Era MA; Department of Urology, Davis Medical Center, University of California at Davis, Sacramento, CA, USA.
  • Sridhar SS; Princess Margaret Hospital, Toronto, ON, Canada.
  • McGrath JS; Department of Surgery, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Exeter, UK.
  • Wright JL; Department of Urology, University of Washington, Seattle, WA, USA.
  • Thorpe AC; Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK.
  • Morgan TM; Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA.
  • Daneshmand S; USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, USA.
  • Holzbeierlein JM; Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA.
  • Bivalacqua TJ; Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • North S; Cross Cancer Institute, Edmonton, AB, Canada.
  • Barocas DA; Department of Oncology, University of Alberta, Alberta, AB, Canada.
  • Lotan Y; Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Grivas P; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Stephenson AJ; Department of Medicine, Division of Oncology, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Shah JB; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • van Rhijn BW; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Spiess PE; Department of Urology, Stanford University School of Medicine, Stanford, CA, USA.
  • Shariat SF; Department of Urology, MD Anderson Cancer Center, Houston, TX, USA.
  • Gontero P; Department of Urology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
BJU Int ; 128(1): 79-87, 2021 07.
Article en En | MEDLINE | ID: mdl-33152179
OBJECTIVES: To assess the efficacy of neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) in a retrospective multicentre cohort of patients with cT2N0M0 bladder cancer (BCa) without preoperative hydronephrosis. PATIENTS AND METHODS: This was a propensity-based analysis of 619 patients. Of these, 316 were treated with NAC followed by RC and 303 with upfront RC. After multiple imputations, inverse probability of treatment weighting (IPTW) was used to account for potential selection bias. Multivariable logistic regression analysis was performed to evaluate the impact of NAC on pathological complete response and downstaging at RC, while IPTW-adjusted Kaplan-Meier curves and Cox regression models were built to evaluate the impact of NAC on overall survival (OS). RESULTS: After IPTW-adjusted analysis, standardised differences between groups were <15%. A complete response (pT0N0) at final pathology was achieved in 94 (30%) patients receiving NAC and nine (3%) undergoing upfront RC. Downstaging to non-muscle-invasive disease (
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Cistectomía / Terapia Neoadyuvante Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: BJU Int Asunto de la revista: UROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Cistectomía / Terapia Neoadyuvante Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: BJU Int Asunto de la revista: UROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido